Literature DB >> 17379834

Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice.

Diana M Shih1, Yu-Rong Xia, Xu-Ping Wang, Susanna S Wang, Noam Bourquard, Alan M Fogelman, Aldons J Lusis, Srinivasa T Reddy.   

Abstract

Paraoxonase 3 (PON3) is a member of the PON family, which includes PON1, PON2, and PON3. Recently, PON3 was shown to prevent the oxidation of low-density lipoprotein in vitro. To test the role of PON3 in atherosclerosis and related traits, 2 independent lines of human PON3 transgenic (Tg) mice on the C57BL/6J (B6) background were constructed. Human PON3 mRNA was detected in various tissues, including liver, lung, kidney, brain, adipose, and aorta, of both lines of Tg mice. The human PON3 mRNA levels in the livers of PON3 Tg mice were 4- to 7-fold higher as compared with the endogenous mouse Pon3 mRNA levels. Human PON3 protein and activity were detected in the livers of Tg mice as well. No significant differences in plasma total, high-density lipoprotein, and very-low-density lipoprotein/low-density lipoprotein cholesterol and triglyceride and glucose levels were observed between the PON3 Tg and non-Tg mice. Interestingly, atherosclerotic lesion areas were significantly smaller in both lines of male PON3 Tg mice as compared with the male non-Tg littermates on B6 background fed an atherogenic diet. When bred onto the low-density lipoprotein receptor knockout mouse background, the male PON3 Tg mice also exhibited decreased atherosclerotic lesion areas and decreased expression of monocyte chemoattractant protein-1 in the aorta as compared with the male non-Tg littermates. In addition, decreased adiposity and lower circulating leptin levels were observed in both lines of male PON3 Tg mice as compared with the male non-Tg mice. In an F2 cross, adipose Pon3 mRNA levels inversely correlated with adiposity and related traits. Our study demonstrates that elevated PON3 expression significantly decreases atherosclerotic lesion formation and adiposity in male mice. PON3 may play an important role in protection against obesity and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379834      PMCID: PMC3740095          DOI: 10.1161/01.RES.0000264499.48737.69

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  33 in total

1.  Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.

Authors:  Bharti Mackness; Rozenn Quarck; Wim Verreth; Mike Mackness; Paul Holvoet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-20       Impact factor: 8.311

2.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Authors:  A D Watson; J A Berliner; S Y Hama; B N La Du; K F Faull; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.

Authors:  Dragomir I Draganov; John F Teiber; Audrey Speelman; Yoichi Osawa; Roger Sunahara; Bert N La Du
Journal:  J Lipid Res       Date:  2005-03-16       Impact factor: 5.922

Review 4.  Adipose tissue, adipokines, and inflammation.

Authors:  Giamila Fantuzzi
Journal:  J Allergy Clin Immunol       Date:  2005-05       Impact factor: 10.793

5.  Atherosclerosis quantitative trait loci are sex- and lineage-dependent in an intercross of C57BL/6 and FVB/N low-density lipoprotein receptor-/- mice.

Authors:  Daniel Teupser; Marietta Tan; Adam D Persky; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-27       Impact factor: 11.205

6.  Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice.

Authors:  Peter F Bodary; Shufang Gu; Yuechun Shen; Alyssa H Hasty; Joshua M Buckler; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-09       Impact factor: 8.311

Review 7.  Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease.

Authors:  Panagiotis Kougias; Hong Chai; Peter H Lin; Qizhi Yao; Alan B Lumsden; Changyi Chen
Journal:  J Surg Res       Date:  2005-06-01       Impact factor: 2.192

8.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family.

Authors:  S L Primo-Parmo; R C Sorenson; J Teiber; B N La Du
Journal:  Genomics       Date:  1996-05-01       Impact factor: 5.736

9.  Genetic and genomic analysis of a fat mass trait with complex inheritance reveals marked sex specificity.

Authors:  Susanna Wang; Nadir Yehya; Eric E Schadt; Hui Wang; Thomas A Drake; Aldons J Lusis
Journal:  PLoS Genet       Date:  2006-02-03       Impact factor: 5.917

Review 10.  Leptin and the regulation of body weight in mammals.

Authors:  J M Friedman; J L Halaas
Journal:  Nature       Date:  1998-10-22       Impact factor: 49.962

View more
  30 in total

Review 1.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

2.  Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule.

Authors:  Juyong Brian Kim; Yu-Rong Xia; Casey E Romanoski; Sangderk Lee; YongHong Meng; Yi-Shou Shi; Noam Bourquard; Ke Wei Gong; Zachary Port; Victor Grijalva; Srinivasa T Reddy; Judith A Berliner; Aldons J Lusis; Diana M Shih
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

3.  Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Authors:  Gerard Aragonès; Anabel García-Heredia; Marta Guardiola; Anna Rull; Raúl Beltrán-Debón; Judit Marsillach; Carlos Alonso-Villaverde; Bharti Mackness; Michael Mackness; Juan Pedro-Botet; Pedro Pardo-Reche; Jorge Joven; Jordi Camps
Journal:  J Lipid Res       Date:  2011-10-14       Impact factor: 5.922

4.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

5.  PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death.

Authors:  E-M Schweikert; A Devarajan; I Witte; P Wilgenbus; J Amort; U Förstermann; A Shabazian; V Grijalva; D M Shih; R Farias-Eisner; J F Teiber; S T Reddy; S Horke
Journal:  Cell Death Differ       Date:  2012-03-23       Impact factor: 15.828

6.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 7.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 8.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

9.  Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone.

Authors:  John F Teiber; Sven Horke; Donovan C Haines; Puneet K Chowdhary; Junhui Xiao; Gerald L Kramer; Robert W Haley; Dragomir I Draganov
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

10.  Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat.

Authors:  Rita Romani; Gianna Evelina De Medio; Simona di Tullio; Rosa Lapalombella; Irene Pirisinu; Vittoria Margonato; Arsenio Veicsteinas; Marina Marini; Gabriella Rosi
Journal:  J Lipid Res       Date:  2008-12-16       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.